Long-term, regular remote ischemic preconditioning improves endothelial function in patients with coronary heart disease

Brazilian Journal of Medical and Biological Research

Volumn 48, Issue 6, 2015, Pages 568-576

  Liang, Y ^a   Li, Y P ^a   He, F ^a   Liu, X Q ^a   Zhang, J Y ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Coronary heart disease; Endothelial function; Remote ischemic preconditioning; STAT 3

Indexed keywords

CD34 ANTIBODY; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PROTEIN KINASE B; STAT PROTEIN; TROPONIN; CD34 ANTIGEN; STAT3 PROTEIN;

ADULT; ARTERY BLOOD FLOW; ARTERY OCCLUSION; ARTICLE; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; ENDOTHELIUM; FEMALE; FLOW CYTOMETRY; FLOW MEDIATED DILATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISCHEMIC HEART DISEASE; ISCHEMIC PRECONDITIONING; LEUKOCYTE COUNT; MALE; MASTECTOMY; MIDDLE AGED; MRNA EXPRESSION ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; AGED; CORONARY DISEASE; ENDOTHELIAL PROGENITOR CELL; HEART INFARCTION PREVENTION; MYOCARDIAL INFARCTION; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; TIME; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

AGED; ANTIGENS, CD34; BLOTTING, WESTERN; CORONARY ARTERY BYPASS; CORONARY DISEASE; ENDOTHELIAL PROGENITOR CELLS; ENDOTHELIUM, VASCULAR; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; ISCHEMIC PRECONDITIONING, MYOCARDIAL; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NITRIC OXIDE SYNTHASE TYPE III; REAL-TIME POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84931080162     PISSN: None     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20144452     Document Type: Article

References (33)

1. Hausenloy DJ, Yellon DM. Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res 2008; 79: 377-386, doi: 10.1093/cvr/cvn114.
2. Heusch G, Schulz R. Remote preconditioning. J Mol Cell Cardiol 2002; 34: 1279-1281, doi: 10.1006/jmcc.2002.2093.
3. Kharbanda RK. Cardiac conditioning: a review of evolving strategies to reduce ischaemia-reperfusion injury. Heart 2010; 96: 1179-1186, doi: 10.1136/hrt.2009.179101.
4. Saxena P, Newman MA, Shehatha JS, Redington AN, Konstantinov IE. Remote ischemic conditioning: evolution of the concept, mechanisms, and clinical application. J Card Surg 2010; 25: 127-134, doi: 10.1111/j.1540-8191.2009.00820.x.
5. Davel AP, Wenceslau CF, Akamine EH, Xavier FE, Couto GK, Oliveira HT, et al. Endothelial dysfunction in cardiovascular and endocrine-metabolic diseases: an update. Braz J Med Biol Res 2011; 44: 920-932, doi: 10.1590/S0100-879X2011007500104.
6. Botker HE, Kharbanda R, Schmidt MR, Bottcher M, Kaltoft AK, Terkelsen CJ, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010; 375: 727-734, doi: 10.1016/S0140-6736(09)62001-8.
7. Bai XY, Liu XC, Yang Q, Tang XD, He GW. The interaction between human urotensin II and vasodilator agents in human internal mammary artery with possible clinical implications. Ann Thorac Surg 2011; 92: 610-616, doi: 10.1016/j.athoracsur.2011.03.094.
8. Rodriguez-Esparragon F, Serna-Gomez JA, Hernandez- Velazquez E, Buset-Rios N, Hernandez-Trujillo Y, Garcia-Bello MA, et al. Homocysteinylated protein levels in internal mammary artery (IMA) fragments and its genotype-dependence. S-homocysteine-induced methylation modifications in IMA and aortic fragments. Mol Cell Biochem 2012; 369: 235-246, doi: 10.1007/s11010-012-1387-7.
9. Lacerda L, Somers S, Opie LH, Lecour S. Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res 2009; 84: 201-208, doi: 10.1093/cvr/cvp274.
10. Xin P, Zhu W, Li J, Ma S, Wang L, Liu M, et al. Combined local ischemic postconditioning and remote preconditioning recapitulate cardioprotective effects of local ischemic preconditioning. Am J Physiol Heart Circ Physiol 2010; 298: H1819-H1831, doi: 10.1152/ajpheart.01102.2009.
11. Tamareille S, Mateus V, Ghaboura N, Jeanneteau J, Croue A, Henrion D, et al. RISK and SAFE signaling pathway interactions in remote limb ischemic perconditioning in combination with local ischemic postconditioning. Basic Res Cardiol 2011; 106: 1329-1339, doi: 10.1007/s00395-011-0210-z.
12. Kerendi F, Kin H, Halkos ME, Jiang R, Zatta AJ, Zhao ZQ, et al. Remote postconditioning. Brief renal ischemia and reperfusion applied before coronary artery reperfusion reduces myocardial infarct size via endogenous activation of adenosine receptors. Basic Res Cardiol 2005; 100: 404-412, doi: 10.1007/s00395-005-0539-2.
13. Loukogeorgakis SP, Williams R, Panagiotidou AT, Kolvekar SK, Donald A, Cole TJ, et al. Transient limb ischemia induces remote preconditioning and remote postconditioning in humans by a K(ATP)-channel dependent mechanism. Circulation 2007; 116: 1386-1395, doi: 10.1161/CIRCULA TIONAHA.106.653782.
14. Jones H, Hopkins N, Bailey TG, Green DJ, Cable NT, Thijssen DH. Seven-day remote ischemic preconditioning improves local and systemic endothelial function and microcirculation in healthy humans. Am J Hypertens 2014; 27: 918-925, doi: 10.1093/ajh/hpu004.
15. Valgimigl i M, Rigolin GM, Fucili A, Porta MD, Soukhomovskaia O, Malagutti P, et al. CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 2004; 110: 1209-1212, doi: 10.1161/01.CIR.0000136813.89036.21.
16. Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R. The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Ther 2008; 120: 172-185, doi: 10.1016/j.pharmthera.2008.08.002.
17. Boengler K, Hilfiker-Kleiner D, Heusch G, Schulz R. Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/ reperfusion. Basic Res Cardiol 2010; 105: 771-785, doi: 10.1007/s00395-010-0124-1.
18. Hausenloy DJ, Lecour S, Yellon DM. Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal 2011; 14: 893-907, doi: 10.1089/ars.2010.3360.
19. Kelly RF, Lamont KT, Somers S, Hacking D, Lacerda L, Thomas P, et al. Ethanolamine is a novel STAT-3 dependent cardioprotective agent. Basic Res Cardiol 2010; 105: 763-770, doi: 10.1007/s00395-010-0125-0.
20. Lecour S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway? J Mol Cell Cardiol 2009; 47: 32-40, doi: 10.1016/j.yjmcc.2009.03.019.
21. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999; 5: 434-438, doi: 10.1038/8462.
22. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 7: 430-436, doi: 10.1038/86498.
23. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, Wang T, Gregg D, Ramaswami P, et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 2003; 108: 457-463, doi: 10.1161/01.CIR.0000082924.75945.48.
24. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600, doi: 10.1056/NEJMoa022287.
25. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999-1007, doi: 10.1056/NEJMoa043814.
26. Rosenzweig A. Circulating endothelial progenitors - cells as biomarkers. N Engl J Med 2005; 353: 1055-1057, doi: 10.1056/NEJMe058134.
27. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967, doi: 10.1126/science.275.5302.964.
28. Fina L, Molgaard HV, Robertson D, Bradley NJ, Monaghan P, Delia D, et al. Expression of the CD34 gene in vascular endothelial cells. Blood 1990; 75: 2417-2426.
29. Salven P, Mustjoki S, Alitalo R, Alitalo K, Rafii S. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/ vascular endothelial precursor cells. Blood 2003; 101: 168-172, doi: 10.1182/blood-2002-03-0755.
30. Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002; 109: 337-346, doi: 10.1172/JCI0214327.
31. Silvestre JS, Gojova A, Brun V, Potteaux S, Esposito B, Duriez M, et al. Transplantation of bone marrow-derived mononuclear cells in ischemic apolipoprotein E-knockout mice accelerates atherosclerosis without altering plaque composition. Circulation 2003; 108: 2839-2842, doi: 10.1161/01.CIR.0000106161.43954.DF.
32. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003; 9: 1370-1376, doi: 10.1038/nm948.
33. Kissel CK, Lehmann R, Assmus B, Aicher A, Honold J, Fischer-Rasokat U, et al. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J Am Coll Cardiol 2007; 49: 2341-2349, doi: 10.1016/j.jacc.2007.01.095.